In order to finish the trial quickly, Glaxo is testing the response generated by the immune system due to the vaccine.

FORBES: Glaxo Goes Head-To-Head With Merck

Whether the U.S. system of ground-based interceptors are the right response quickly became a matter of debate Friday.

WSJ: U.S. to Boost Missile Defenses in Response to North Korea